Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

DNA methylation patterns are disrupted in various malignancies, suggesting a role in the
development of cancer, but genetic aberrations directly linking the DNA methylation …

Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …

Abstract STOP second generation (2G)–tyrosine kinase inhibitor (TKI) is a multicenter
observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid …

Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …

Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …

Abstract Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients
compares nilotinib and imatinib in patients with newly diagnosed chronic myeloid leukemia …

Cancer is a group of diseases characterized by the uncontrolled growth and spread of
abnormal cells and oncology is a branch of medicine that deals with tumors. The last decade …

Background Nilotinib has shown greater efficacy than imatinib in patients with newly
diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic …